Evidence map›Paper›PMID 37514978›Full record

ArticleVaccines2023

Expression of

Allison C Vilander, Kimberly Shelton, Alora LaVoy, Gregg A Dean

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.4field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. RecombinantFuture microbiology · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Prebiotic effect of galacto-Applied and environmental microbiology · 2024
    Article
  8. Vaccines · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Allison C VilanderDepartment of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.
Kimberly SheltonDepartment of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.ORCID 0009-0003-4679-3018
Alora LaVoyDepartment of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.
Gregg A DeanDepartment of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.ORCID 0000-0001-7025-9550
Colorado State University · US

Funding

Biomedical Research Training for VeterinariansT32OD010437 · OD · COLORADO STATE UNIVERSITY · PI Gregg A Dean, KELLY S SANTANGELO · 2012 to 2026
$6.2M
Novel recombinant Rotavirus vaccine utilizing the probiotic microorganism Lactobacillus acidophilusR01AI141603 · NIAID · COLORADO STATE UNIVERSITY · PI ABDO, ZAID, BARRANGOU, RODOLPHE · 2020 to 2024
$3.6M
NIAID NIH HHS R01 AI141603NIH HHS T32 OD010437
6 · The paper itself

Abstract

The development of lactic acid bacteria as mucosal vaccine vectors requires the identification of robust mucosal adjuvants to increase vaccine effectiveness. The

Indexed as

adjuvantFimHlactic acid bacteriaLactobacillus acidophilusmucosal vaccines

Identifiers

PMID37514978
PMCPMC10384470
OpenAlexW4382465740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.